---
id: aad-alopecia-areata-2024
title: "AAD 2024 Guidelines of Care for the Management of Alopecia Areata"
short_title: "AAD Alopecia Areata 2024"

organization: American Academy of Dermatology
collaborators: null
country: US
url: https://www.aad.org/clinical-guidelines
doi: null
pmid: null
open_access: true

specialty: dermatology
guideline_type: clinical-practice
evidence_system: AAD GRADE
conditions:
  - alopecia areata
  - hair loss
  - autoimmune alopecia
tags:
  - JAK inhibitors
  - baricitinib
  - ritlecitinib
  - intralesional corticosteroids
  - topical immunotherapy

publication_date: 2024-04-01
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 AAD clinical practice guideline on the management of alopecia areata (AA) in adults and children.

## Key Recommendations

### General Approach
- Assess extent of hair loss (patchy, totalis, universalis) and psychosocial impact.
- Spontaneous remission occurs in ~50% of patients with limited patchy AA within 1 year, but relapse is common.

### Topical/Intralesional Therapies (Limited Disease)

#### Intralesional Corticosteroids
- **First-line for patchy AA**: Triamcinolone acetonide (2.5-10 mg/mL) injected into affected scalp every 4-6 weeks.

#### Topical Corticosteroids
- High-potency topical steroids (clobetasol) may be used, especially in children or those averse to injections.

#### Topical Immunotherapy
- Contact sensitizers (DPCP, SADBE) induce allergic contact dermatitis to stimulate regrowth. Effective in some patients with extensive disease.

#### Topical Minoxidil
- Adjunctive therapy to enhance regrowth; limited efficacy as monotherapy.

### Systemic Therapies (Extensive or Refractory Disease)

#### JAK Inhibitors (FDA-Approved)
- **Baricitinib (Olumiant)**: JAK1/2 inhibitor. Approved for severe AA in adults.
- **Ritlecitinib (Litfulo)**: JAK3/TEC inhibitor. Approved for AA in patients â‰¥12 years.
- Highly effective; regrowth seen in significant proportion of patients.
- Monitor for infections, lipid abnormalities, VTE risk.

#### Off-Label Systemic Options
- Oral corticosteroids (short-term pulse therapy).
- Methotrexate, cyclosporine: May be considered for refractory cases.

### Patient Counseling
- Psychological support, referral to support groups.
- Wigs, scarves, cosmetic camouflage.
- Discuss realistic expectations and potential for relapse.
